Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 373,600 | 1,503,100 | 1,167,800 | 827,700 | 338,200 |
| Depreciation Amortization | 34,700 | 134,800 | 101,800 | 68,200 | 32,400 |
| Income taxes - deferred | -42,600 | -41,400 | 20,100 | 16,200 | 10,800 |
| Accounts receivable | -57,800 | -91,100 | -97,900 | -135,900 | -89,500 |
| Other Working Capital | -119,400 | 174,500 | 103,700 | -41,700 | -110,800 |
| Other Operating Activity | 104,800 | 52,200 | 63,000 | 92,100 | 119,400 |
| Operating Cash Flow | $293,300 | $1,732,100 | $1,358,500 | $826,600 | $300,500 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | 168,500 | N/A |
| PPE Investments | -72,700 | -325,800 | -236,000 | -175,300 | -106,000 |
| Net Acquisitions | N/A | -13,100 | -5,700 | -5,700 | N/A |
| Purchase Of Investment | -202,100 | -1,879,300 | -825,000 | -411,500 | -77,400 |
| Sale Of Investment | 502,000 | 529,200 | 332,100 | 50,000 | 136,800 |
| Purchase Sale Intangibles | N/A | -4,000 | N/A | N/A | N/A |
| Other Investing Activity | 2,300 | -33,500 | -22,000 | -5,200 | -3,100 |
| Investing Cash Flow | $229,500 | $-1,722,500 | $-756,600 | $-379,200 | $-49,700 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 5,200 | 5,200 | 14,000 | 4,500 |
| Debt Repayment | N/A | -7,000 | -6,900 | N/A | -4,900 |
| Common Stock Issued | 37,500 | N/A | 124,700 | 85,800 | 31,600 |
| Common Stock Repurchased | -405,600 | -512,800 | -416,300 | -414,500 | -302,600 |
| Other Financing Activity | 0 | 158,300 | -1,000 | -18,600 | -2,900 |
| Financing Cash Flow | $-368,100 | $-356,300 | $-294,300 | $-333,300 | $-274,300 |
| Exchange Rate Effect | 13,200 | 13,900 | 12,100 | 11,600 | 14,200 |
| Beginning Cash Position | 867,400 | 1,200,200 | 1,200,200 | 1,200,200 | 1,200,200 |
| End Cash Position | 1,035,300 | 867,400 | 1,519,900 | 1,325,900 | 1,190,900 |
| Net Cash Flow | $167,900 | $-332,800 | $319,700 | $125,700 | $-9,300 |
| Free Cash Flow | |||||
| Operating Cash Flow | 293,300 | 1,732,100 | 1,358,500 | 826,600 | 300,500 |
| Capital Expenditure | -72,700 | -325,800 | -236,000 | -175,300 | -106,000 |
| Free Cash Flow | 220,600 | 1,406,300 | 1,122,500 | 651,300 | 194,500 |